Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer

NCT00001493 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

NIH

Sponsor class

Conditions

Breast Neoplasms
Neoplasm Metastasis

Interventions

GENETIC: peripheral blood progenitor cells carrying MDR1

Sponsor

National Cancer Institute (NCI)